Provided by Tiger Fintech (Singapore) Pte. Ltd.

Perspective Therapeutics

2.20
-0.1000-4.35%
Post-market: 2.310.1100+5.00%17:03 EDT
Volume:657.19K
Turnover:1.48M
Market Cap:162.91M
PE:-1.85
High:2.37
Open:2.33
Low:2.19
Close:2.30
Loading ...

Perspective Therapeutics (CATX) Receives a Hold from Bank of America Securities

TIPRANKS
·
28 Mar

Perspective Therapeutics Price Target Maintained With a $11.00/Share by Wedbush

Dow Jones
·
27 Mar

Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX)

TIPRANKS
·
27 Mar

RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk

MT Newswires Live
·
27 Mar

Perspective Therapeutics Reports 2024 Earnings and Clinical Progress

TIPRANKS
·
27 Mar

BRIEF-Perspective Therapeutics: Expect To Have Sufficient Funding Into Late 2026

Reuters
·
27 Mar

Perspective Therapeutics Inc: Expect to Have Sufficient Funding Into Late 2026

THOMSON REUTERS
·
27 Mar

Perspective Therapeutics FY 2024 GAAP EPS $(1.23) Misses $(0.87) Estimate, Sales $1.454M Beat $1.348M Estimate

Benzinga
·
27 Mar

Press Release: Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Dow Jones
·
27 Mar

Perspective Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Mar

Perspective Therapeutics Starts Dosing New Cohort for Melanoma Tumor Treatment Therapy

MT Newswires Live
·
17 Mar

Perspective Therapeutics Announces First Patient Dosed With [212Pb]VMT01 In Combination With Nivolumab In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma

Reuters
·
17 Mar

Perspective Therapeutics Announces First Patient Dosed With [212PB]Vmt01 in Combination With Nivolumab in a Phase 1/2a Study of Mc1r-Positive Metastatic Melanoma

THOMSON REUTERS
·
17 Mar

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

GlobeNewswire
·
17 Mar

Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Perspective Therapeutics (CATX) and Edesa Biotech (EDSA)

TIPRANKS
·
13 Mar

HC Wainwright Initiates Coverage on Perspective Therapeutics With Buy Rating, $10 Price Target

MT Newswires Live
·
13 Mar